Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Vaxcyte priced a $500 million equity offering at $64 per share and a $500 million convertible notes offering. Proceeds are expected to support VAX-31 development, manufacturing expansion, inventory and potential U.S. launch preparations.
Vaxcyte announced that its offerings are expected to close on October 9.
SAN CARLOS, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of concurrent underwritten public offerings of 7,412,500 shares of common stock, pre-funded warrants to purchase 400,000 shares of common stock and $500 million ag